Please ensure Javascript is enabled for purposes of website accessibility

Why Vertex Pharmaceuticals Stock Is Jumping Today

By Keith Speights – Dec 1, 2021 at 12:28PM

Key Points

  • Vertex reported positive phase 2 results for VX-147 in treating a rare genetic kidney disease.
  • It achieved a significant reduction in protein in the urine and was well tolerated.
  • The company plans to advance the drug into pivotal studies in Q1 of 2022.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced encouraging phase 2 results.

What happened

Shares of Vertex Pharmaceuticals (VRTX -1.58%) were jumping 8.2% as of 12:01 p.m. ET on Wednesday. The nice gain came after the big biotech announced positive results from a phase 2 proof-of-concept study evaluating VX-147 in treating patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).

FSGS is a kidney disease caused by variants of the APOL1 gene. Individuals with FSGS can require dialysis or kidney transplants. Some eventually die of the disease, which currently has no approved therapies targeting the underlying cause.

Two scientists sitting in front of monitors.

Image source: Getty Images.

So what

Vertex reported that participants in the phase 2 study who were treated with VX-147 had "statistically significant, substantial, and clinically meaningful mean reduction in proteinuria [proteins in the urine] of 47.6%" at 13 weeks after dosing compared to their baseline levels. The company also stated that the experimental drug was well tolerated with no serious adverse events related to it and no treatment discontinuations due to adverse events.

These positive results provided a big boost for Vertex when it was much needed. Prior to today, the biotech stock had fallen nearly 21% year to date. The decline was primarily due to Vertex's disappointing results earlier this year for its alpha-1 antitrypsin deficiency (AATD) program. Investors now have reason to be more confident about Vertex's prospects beyond cystic fibrosis (CF), an indication where the company has achieved tremendous success.

Now what

Vertex now plans to advance VX-147 into pivotal development in the first quarter of 2022. The company's clinical studies will target APOL1-mediated kidney disease, including (but not limited to) FSGS.

Keith Speights owns shares of Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.